(Q52932186)

English

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

scientific article published in July 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

plaque psoriasis

1 reference

based on heuristic

inferred from title

author name string

L Dubertret

1

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

W Sterry

2

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

J D Bos

3

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

S Chimenti

4

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

S Shumack

5

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

C G Larsen

6

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

N H Shear

7

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

K A Papp

8

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

CLEAR Multinational Study Group

9

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

language of work or name

0 references

publication date

1 July 2006

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

British Journal of Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

155

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

1

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

170-181

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

The immunologic basis for the treatment of psoriasis with new biologic agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

The pathogenesis of psoriasis: immunological facts and speculations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

The role of adhesion molecules, chemotactic factors, and cytokines in inflammatory and neoplastic skin disease--1990 update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Nonparametric estimation of a delay distribution based on left-censored and right-truncated data

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Identifiers

10.1111/J.1365-2133.2006.07344.X

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52932186&oldid=1538379063"